What is compounding?
Drug compounding is often regarded as the process of combining or mixing drugs to create a medication tailored to the needs of an individual patient.
The generic form of Vetmedin is Pimobendan.
Vetmedin is in limited supply. Orders placed will be shipped as product continues to come off backorder.
Incurin Tablets are an effective treatment for the control of estrogen-responsive urinary incontinence in dogs that have undergone surgical removal of the ovaries and uterus (ovariohysterectomy). This medication has been used effectively worldwide for more than 12 years. Incurin Tablets require a prescription from your veterinarian.
Incurin Tablets contain the active ingredient estriol, a natural estrogen, which increases the resting muscle tone of the urethra in female dogs and can be used in the treatment of urinary incontinence due to estrogen depletion. It is given once a day with a starting dose of two tablets for any female dog, regardless of age or weight. The dose of Incurin Tablets is then titrated down over time to the lowest effective dose.
Incurin Tablets are indicated for the control of estrogen-responsive urinary incontinence inovariohysterectomized female dogs.
Incurin Tablets is a registered trademark of Intervet Inc., d/b/a Merck Animal Health, a subsidiary of Merck & Co. Inc.
The dose of Incurin Tablets is not dependent upon body weight. All dogs should receive an initial dose of 2 mg Incurin Tablets (2 tablets) orally once per day for a minimum of 14 days. After urinary incontinence is controlled, the lowest effective daily dose of Incurin Tablets should be determined by decreasing the dose in a step-wise manner from 2 mg once daily (2 tablets) to 1 mg oncedaily (1 tablet), then 0.5 mg once daily (1/2 tablet) depending upon the response of the individual dog. There should be a minimum of 7 days between each dose adjustment. After the lowest daily dose that controls urinary incontinence is identified, the dose may be decreased further by administering once every two days. Dogs should not receive more than 2 mg Incurin Tablets per day (2 tablets). If thedog does not respond to 2 mg of Incurin Tablets per day, the diagnosis should be re-assessed.
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Not for human use. Keep out of the reach of children. Women who are of child-bearing age or those who are breast feeding should use caution when administering Incurin Tablets. Wash your hands with soap and water after administration to avoid exposure to the drug. Consult a physician in case of accidental ingestion by humans.
Some estrogens have been associated with bone marrow changes and an increased risk of mammary tumors. However, target animal safety study results and foreign post-market pharmacovigilance data for Incurin Tablets have shown that estriol-treated dogs are at low risk for developing these conditions.
Evaluation of factors contributing to urinary incontinence should be considered prior of administration of Incurin Tablets.
Do not use with other estrogens. The concomitant use of Incurin Tablets with other estrogens has not been evaluated.
The concomitant use of Incurin Tablets with glucocorticoids has not been evaluated.
The use of Incurin Tablets in dogs with liver disease has not been evaluated.
The safe use of Incurin Tablets has not been evaluated in intact female dogs, pregnant or lactating dogs, male dogs, and dogs less than 1 year of age.
Please contact your veterinarian if your pet is suffering from gastrointestinal and estrogenic effects, or if the color or texture of your pet’s vulva changes.
Store at or below 25C (77°F) with excursions permitted to 40°C (104°F)